Could a broccoli compound help schizophrenia symptoms?
NCT ID NCT07652866
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a daily supplement of sulforaphane, a compound found in broccoli sprouts, can improve negative symptoms (like lack of motivation) and thinking problems in people with schizophrenia. Sixty participants aged 12 to 45 who are stable on antipsychotic medication will receive either sulforaphane or a placebo for 12 weeks, followed by an optional 12-week open-label phase. The study will measure changes in symptom scales and brain imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sulforaphane (a compound found in broccoli sprouts)
What this could lead to
If it works, this could point toward a new way to help with hard-to-treat symptoms like lack of motivation and trouble thinking clearly in schizophrenia.
What could go wrong
This is a small, early-stage trial with only 60 people. The supplement may not work better than a placebo, and results may not apply to everyone with schizophrenia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xiangya Second Hospital
Changsha, China, 410001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••